Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Ester, Del Signore"'
Autor:
Valeria Fuorivia, Ilaria Attili, Carla Corvaja, Riccardo Asnaghi, Ambra Carnevale Schianca, Pamela Trillo Aliaga, Ester Del Signore, Gianluca Spitaleri, Antonio Passaro, Filippo de Marinis
Publikováno v:
Current Oncology, Vol 31, Iss 9, Pp 5121-5139 (2024)
The ever-growing knowledge regarding NSCLC molecular biology has brought innovative therapies into clinical practice; however, the treatment situation in the non-metastatic setting is rapidly evolving. Indeed, immunotherapy-based perioperative treatm
Externí odkaz:
https://doaj.org/article/3ed05c0b4ba740369ca1630364d8a082
Autor:
Gianluca Spitaleri, Pamela Trillo Aliaga, Ilaria Attili, Ester Del Signore, Carla Corvaja, Chiara Corti, Edoardo Crimini, Antonio Passaro, Filippo de Marinis
Publikováno v:
Current Oncology, Vol 30, Iss 5, Pp 5072-5092 (2023)
ALK translocation amounts to around 3–7% of all NSCLCs. The clinical features of ALK+ NSCLC are an adenocarcinoma histology, younger age, limited smoking history, and brain metastases. The activity of chemotherapy and immunotherapy is modest in ALK
Externí odkaz:
https://doaj.org/article/237f3ac30475444a97d7a0d94817d83b
Autor:
Ilaria Attili, Carmine Valenza, Celeste Santoro, Gabriele Antonarelli, Pamela Trillo Aliaga, Ester Del Signore, Chiara Catania, Gianluca Spitaleri, Antonio Passaro, Filippo de Marinis
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundFollowing the introduction of immunotherapy (IO) in the first-line (1L) treatment in patients with non-small cell lung cancer (NSCLC) without sensitizing EGFR/ALK mutations, increasing real-world data depict how difficult it is to replicate
Externí odkaz:
https://doaj.org/article/b82967c179b1415b8e47bb150aadac48
Publikováno v:
Patient Experience Journal (2020)
When you get ill, the first thing that comes to your mind is, “Will I make it? Will I survive?". COVID19 has a major impact on mental health. A sadness that inundates us like a river in flood and which we cannot hold back. But the thing that tormen
Externí odkaz:
https://doaj.org/article/6de39efdeea945b7a0fb961d07e4b4dd
Autor:
Chiara Catania, Gianluca Spitaleri, Ester Del Signore, Ilaria Attili, Davide Radice, Valeria Stati, Letizia Gianoncelli, Stefania Morganti, Filippo de Marinis
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
In February 2020, Italy became one of the first countries to be plagued by the SARS-CoV-2 pandemic, COVID-19. In March 2020, the Italian government decreed a lockdown for the whole country, which overturned communication systems, hospital organizatio
Externí odkaz:
https://doaj.org/article/c482541459014b8eae0d08837e0da789
Autor:
Filippo de Marinis, Ilaria Attili, Stefania Morganti, Valeria Stati, Gianluca Spitaleri, Letizia Gianoncelli, Ester Del Signore, Chiara Catania, Cristiano Rampinelli, Emanuela Omodeo Salè, Lorenzo Spaggiari, Fabrizio Mastrilli, Antonio Passaro
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
A novel coronavirus causing severe acute respiratory syndrome (SARS), named SARS-CoV-2, was identified at the end of 2019. The spread of coronavirus disease 2019 (COVID-19) has progressively expanded from China, involving several countries throughout
Externí odkaz:
https://doaj.org/article/b166a3ec616645e09a8354bb34f21503
Publikováno v:
Clinical Management Issues, Vol 4, Iss 1S, Pp 3-7 (2015)
We report the case of a 51-year-old woman with limited Small Cell Lung Cancer (SCLC). Cytological diagnosis has been made by fibroscopy. Chemotherapy schedule was cisplatin 30 mg/mq and VP-16 100 mg/mq days 1,2,3 q21 as first line treatment. The seru
Externí odkaz:
https://doaj.org/article/b25af28d89884b4b849884a47f771108
Autor:
Elena Guerini-Rocco, Valeria Stati, Davide Radice, Filippo de Marinis, Ester Del Signore, Antonio Passaro, Letizia Gianoncelli, Chiara Catania, Caterina Fumagalli, Massimo Barberis, Gianluca Spitaleri
Publikováno v:
Anticancer Research. 40:427-433
BACKGROUND/AIM The role of anti-PD1/PD-L1 therapy (IO) in NSCLC harboring driver mutations is questionable. This study aimed to examine the efficacy of IO in patients with non-small cell lung cancer (NSCLC) with a KRAS mutation (KRAS+). PATIENTS AND
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52165fe81f7d89b72427e65f53da6261
https://doi.org/10.21873/anticanres.13970
https://doi.org/10.21873/anticanres.13970
Publikováno v:
Clinical Management Issues, Vol 3, Iss 2, Pp 63-69 (2009)
We report the case of a 53-year-old woman with brain metastatic Non-Small Cell Lung Cancer (NSCLC). Diagnosis was made during brain surgery. Brain metastases were treated both with surgery and radiotherapy. The chemotherapy schedule was cisplatin 75
Externí odkaz:
https://doaj.org/article/7b6a7d562f574e438fb6436bb9ab7b8f
Publikováno v:
Clinical lung cancer. 23(2)
Surgery is the best option for patients with early stage non-small cell lung cancer (NSCLC). However, the rate of local and metastatic recurrences following surgery alone is high, especially in NSCLC patients with N2 lymph node involvement. A recent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9779ec8ef584ac0097558b439aa471c
https://pubmed.ncbi.nlm.nih.gov/34952792
https://pubmed.ncbi.nlm.nih.gov/34952792